Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pleural Disorders: Types and Brief Description

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:

Pleural Effusion II: Symptoms and Management

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:

Pleural Effusion I: Introduction

Pleural Effusion I: Introduction

Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's criteria,...

Pleura of the Lungs

Pleura of the Lungs

The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Pneumothorax-II

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Pleural Infection in Adults: Integrating Medical and Surgical Management for Optimal Outcomes.

Thoracic surgery clinics·2026

Same author

Correction: Prisciandaro et al. Anatomical Versus Non-Anatomical Pulmonary Metastasectomy: European Multicentre Analysis. <i>Cancers</i> 2026, <i>18</i>, 1037.

Cancers·2026

Same author

Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Donor-recipient sex differences: Implications for immunologic outcomes but no impact on survival after lung transplantation.

JHLT open·2026

Same author

The 2026 American Association for Thoracic Surgery Expert Consensus Document: Evaluation and management of N2+ non-small cell lung cancer.

The Journal of thoracic and cardiovascular surgery·2026

Same journal

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.

Future oncology (London, England)·2026

Same journal

Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.

Future oncology (London, England)·2026

Same journal

Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015-2024): real-world evidence from 4,920 cases.

Future oncology (London, England)·2026

Same journal

VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma.

Future oncology (London, England)·2026

Same journal

Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy.

Future oncology (London, England)·2026

Same journal

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.

Future oncology (London, England)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Malignant pleural mesothelioma.

Rolf A Stahel¹, Emanuela Felley-Bosco, Isabelle Opitz

¹Laboratory of Molecular Oncology, Clinic and Policlinic of Oncology, University Hosptial, CH-8091 Zürich, Switzerland. rolf.stahel@usz.ch

Future Oncology (London, England)

|April 21, 2009

Summary

This summary is machine-generated.

Malignant pleural mesothelioma diagnosis and treatment require a multidisciplinary approach. Current chemotherapy combines cisplatin with pemetrexed, while surgery and novel therapies are under investigation.

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Related Experiment Videos

Last Updated: Jun 23, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Area of Science:

Oncology
Thoracic Surgery
Molecular Biology

Background:

Malignant pleural mesothelioma presents diagnostic and therapeutic challenges.
A multidisciplinary approach is essential for patient management.
Key molecular events include neurofibromatosis-2 gene inactivation and INK4alpha/ARF.

Purpose of the Study:

To review current diagnostic and therapeutic strategies for malignant pleural mesothelioma.
To discuss the role of chemotherapy, surgery, and emerging treatments.

Main Methods:

Review of diagnostic methods including thoracoscopic biopsy and immunohistochemistry.
Analysis of chemotherapy regimens, particularly cisplatin and pemetrexed.
Evaluation of surgical interventions and multimodality treatment approaches.

Main Results:

Cisplatin plus pemetrexed is the preferred first-line chemotherapy based on Phase III trials.
Surgical options range from pleurectomy/decortication to extrapleural pneumonectomy.
Multimodality approaches show encouraging results, with ongoing research into neoadjuvant/adjuvant therapies.

Conclusions:

Malignant pleural mesothelioma management necessitates a comprehensive, multidisciplinary strategy.
Chemotherapy, surgery, and novel targeted therapies are integral to improving outcomes.
Further research is needed to define optimal second-line chemotherapy and the role of radiotherapy and new molecularly targeted agents.